<div id="readability-page-1">New insider activity at Cosmos Holdings ( (COSM) ) has taken place on January 26, 2026.<h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul> Cosmos Holdings has seen a notable insider buy, as CEO Grigorios Siokas acquired 90,325 shares of the company’s stock in a recent transaction. The total value of this purchase amounts to $44,259, signaling a tangible financial commitment from the company’s top executive and potentially reflecting his confidence in the firm’s future prospects. Recent Updates on COSM stock In the last 24 hours, Cosmos Health’s stock activity has been driven by a series of operational and strategic announcements rather than explicit analyst price-target revisions. The company highlighted strong growth at its Greek distribution subsidiary Cosmofarm, which added nearly 100 new pharmacy customers in 2025, improving unit economics through higher revenue and profitability per customer, aided by better route density, optimized order execution, and operating leverage. Management’s expectation that similar or faster customer growth will continue into 2026, along with the rollout of three new delivery routes in the densely populated Attica region and ongoing investment of about $1 million in advanced automation (ROWA and A‑frame robotic systems) designed to materially increase capacity and support roughly $40 million in potential incremental annual revenue, could underpin more constructive views on the firm’s long-term earnings power. In parallel, the newly announced manufacturing and supply agreement via Cana Laboratories to produce the PathMuscle pharmaceutical product for Libytec, with firm minimum volumes and a multi‑year production outlook above 1.2 million units subject to demand, strengthens Cosmos Health’s contracted revenue visibility and diversification within the Greek pharmaceutical market. Together, these developments provide a clearer path to scaling revenue and improving margins, which are the key fundamental reasons that would typically inform any recent or future changes in analysts’ valuation frameworks or sentiment, even though specific target or rating details were not disclosed in the provided articles. Spark’s Take on COSM Stock According to Spark, TipRanks’ AI Analyst, COSM is a Underperform. The score is driven primarily by weak financial performance (losses and negative cash flow) and bearish technicals (below key moving averages with negative MACD). Valuation is constrained by unprofitability (negative P/E), and the Nasdaq non-compliance notice adds additional downside risk. To see Spark’s full report on COSM stock, click here. More about Cosmos Holdings YTD Price Performance: -0.40% Average Trading Volume: 778,118 Technical Sentiment Signal: Strong Sell Current Market Cap: $18.65M</div>

Cosmos Holdings CEO Grigorios Siokas purchased 90,325 shares for $44,259, indicating confidence in the company's future. Recent operational updates show strong growth at its Greek subsidiary, Cosmofarm, with nearly 100 new pharmacy customers added in 2025. The company plans to invest $1 million in automation to boost capacity and revenue. A new manufacturing agreement with Cana Laboratories enhances revenue visibility. However, TipRanks' AI Analyst rates COSM as Underperform due to weak financials and bearish technicals, with a current market cap of $18.65M and a YTD price performance of -0.40%.

Tip Ranks

Invesco Pharmaceuticals ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

VG Health

VanEck Pharmaceutical ETF

VanEck Biotech ETF

iShares US Medical Devices

iShares Global Healthcare

iShares Biotechnology ETF

Cosmos Health

ALPS Medical Breakthrough

SPDR Pharmac

SPDR S&P Biotech

SPDR S&P Health Equip

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Cosmos Holdings CEO Makes Bold Insider Move With Fresh Share Purchase